Frequent presence of Helicobacter pylori infection in chronic urticaria.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to C C Geilen.
Explore the source record for details and available documents.
In the present review we have attempted to give an overview of the role of sphingolipids in skin homoeostasis. Sphingolipid metabolites are emerging as potent second messengers in diverse cellular signaling pathways. In the skin little is known about sphingolipids in signaling events. In various cell populations it has been shown that different sphingolipid metabolites have opposing effects on the biological outcome of a stimulus. Therefore, the term 'sphingolipid rheostat' has been established and has also been shown to exist in skin-derived cell populations. In many cells ceramide is a mediator of proliferation inhibition and apoptosis, whereas sphingosine-1-phosphate acts more like a growth factor and reverses ceramide effects. In keratinocytes extracellular and intracellular ceramides play important roles. Extracellular ceramides are necessary for the water retention capacity and for maintaining the permeability barrier of the skin. Intracellular ceramides cause differentiation of keratinocytes. Until now less is known about the effect of other sphingolipid metabolites in the skin.
We report a 5-year-old boy presenting with multiple elastic type nevi and osteopoikilosis who was diagnosed as having Buschke-Ollendorff syndrome at an early age. Connective tissue lesions may present as the main symptom of varying clinical entities with different outcomes. Differential diagnosis includes papular elastorrhexis, fibroelastolytic papules of the neck, papular acne scars, and late onset focal dermal elastosis. Rare genodermatoses, i.e. Buschke-Ollendorff syndrome, pseudoxanthoma elasticum, juvenile hyaline fibromatosis and familiar cutaneous collagenoma should be carefully evaluated to provide appropriate genetic counseling and to avoid unnecessary treatment procedures.
Psoriasis is one of the most common skin diseases. A variety of molecular alterations has been identified in the active, lesional epidermis and dermis of psoriasis, but the pathogenesis still remains unexplained. Therefore, all antipsoriatic therapeutic regimens are symptomatic. Although there is no cure for psoriasis, a variety of therapeutic modalities is available to reduce the severity and increase the life quality of the patient. In cases with mild to moderate psoriasis, topical therapy (tars, dithranol, topical corticosteroids, and vitamin D derivatives) is the most appropriate choice for initial treatment. For patients with more severe, recalcitrant psoriasis, application of UV-radiation and systemic therapies (e.g. retinoids, methotrexate, cyclosporine A) are available. These modalities are more effective than topical therapy but they are also associated with significant cutaneous and/or systemic adverse effects and a risk-benefit ratio must be taken into account. In recent years, a variety of new approaches and substances has been developed. Their efficacy and safety should be proven in the future.